Blackstone invests $2 billion in Alnylam, boosting gene-silencing drug development [Reuters (UK)]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Reuters
Alnylam's gene-silencing efforts get $2 billion Blackstone backing - Reuters 3 Min Read (Reuters) - Blackstone Group Inc ( BX.N ) said on Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc ( ALNY.O ) through an equity-and-debt deal, giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds. Alnylam is the first drugmaker to win U.S. approval for a treatment using the Nobel prize-winning RNA interference (RNAi) technology and is currently developing other RNAi drugs to treat a range of conditions, including rare bleeding disorders. Earlier this month, the company also agreed to develop treatments for the new coronavirus with Vir Biotechnology Inc ( VIR.O ). The private equity giant is providing $1 billion of the funding in exchange for half of the royalties on global sales of Alnylam’s cholesterol therapy inclisiran, currently under review by U.S. and European regulators. Wall Street analysts noted that the deal bolsters
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d-)" rating to a "hold (c-)" rating.MarketBeat
- JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal [Yahoo! Finance]Yahoo! Finance
- Adimab Reports Strong Partnering Year for 2025 [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website